GLP-1 litigation · Evidence guide
The GLP-1 cases focus on gastrointestinal injuries and warning questions
The federal GI-injury MDL covers several medicines and thousands of actions. The manufacturers deny the allegations, and current FDA labels supply important context without deciding individual cases.
What plaintiffs allege—and what manufacturers say
The court describes lawsuits alleging that specified GLP-1 medicines caused gastroparesis or other gastrointestinal injuries and that warnings were inadequate. The court also states plainly that the Novo Nordisk defendants and Eli Lilly deny those allegations.
The gastrointestinal-injury cases are coordinated in MDL 3094 in the Eastern District of Pennsylvania before Judge Karen Marston. JPML listed 3,928 pending actions on August 3, 2026.
What current FDA labels establish
Current FDA-approved labeling for Ozempic and Mounjaro says gastrointestinal adverse reactions can sometimes be severe and that the products are not recommended in patients with severe gastroparesis. The labels also report trial and postmarketing information using product-specific language.
A label is essential evidence, but it does not resolve every lawsuit. It does not by itself show that a medicine caused one person's condition or answer whether a warning at an earlier time met the law governing that person's claim.
Where the federal proceeding stands
An amended order filed April 30, 2026 requires plaintiffs in the MDL to complete fact sheets and provide supporting records. That process gathers product, use and injury information for the litigation.
The order is procedural. It does not decide causation, warning adequacy or liability, and an MDL listing does not say whether any reader has a claim.
Verification ledger
Primary sources
MDL 3094 — GLP-1 RA Products Liability Litigation
The court's description of allegations, products and manufacturers' denial.
About · 2026 monthly conferences
Amended Case Management Order No. 12
The current plaintiff-fact-sheet order.
Document 656, filed April 30, 2026
Ozempic prescribing information
Current FDA-approved gastrointestinal warning language.
Sections 5.6-5.7 · Reference ID 5808230
Mounjaro prescribing information
Current FDA-approved gastrointestinal warning language.
Sections 5.5-5.6 · Reference ID 5716211